Drug Approval | October 06, 2021
EMA authorises booster dose of Moderna’s Spikevax
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
A total of 8308 stores are open across India and medicines are priced at affordable rates
The initiative will create an integrated network of Critical Care Units (CCUs) across the Apollo Hospitals network but also in partnership with non-Apollo units in India and overseas
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
A total of 707 district hospitals across all states and union territories participated in the performance assessment. The Health Management Information System (HMIS) data for the year 2017–18 has been used as a baseline for this exercise
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
The global wellness market is valued at more than US $ 1.5 trillion, with annual growth of 5-10 per cent
Subscribe To Our Newsletter & Stay Updated
